Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[DNA informs on ancient partner choice].

Medecine sciences : M/S·2026

Same author

[TimeVaults provide recordings of past cellular activity].

Medecine sciences : M/S·2026

Same author

[In vivo CAR-Ts, a significant breakthrough].

Medecine sciences : M/S·2026

Same author

[House of cards?]

Medecine sciences : M/S·2026

Same author

[Towards gene therapy for Hutington's disease].

Medecine sciences : M/S·2025

Same author

[DNA reveals the living world].

Medecine sciences : M/S·2025

Search research articles

Related Experiment Video

Updated: Feb 17, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

[CAR-T immunotherapy, a regulatory milestone].

Bertrand Jordan¹

¹UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS, Espace éthique méditerranéen, hôpital d'adultes la Timone, 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France ; CoReBio PACA, case 901, parc scientifique de Luminy, 13288 Marseille Cedex 09, France.

Medecine Sciences : M/S

|December 5, 2017

Summary

This summary is machine-generated.

The first FDA-approved chimeric antigen receptor (CAR-T) therapy shows excellent results for recurrent pediatric acute lymphoblastic leukemia (ALL), offering long-term remission. Despite high costs, CAR-T therapies are poised to significantly impact future cancer treatment strategies.

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: Feb 17, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Oncology
Immunotherapy
Biotechnology

Background:

The U.S. Food and Drug Administration (FDA) has approved the first therapy utilizing chimeric antigen receptors (CAR-T).
CAR-T therapy represents a significant advancement in personalized cancer treatment.

Purpose of the Study:

To evaluate the efficacy and implications of the first FDA-approved CAR-T therapy.
To discuss the role of CAR-T therapy in managing challenging pediatric cancers.

Main Methods:

Clinical assessment of patient outcomes with CAR-T therapy.
Economic analysis comparing treatment cost to clinical benefit.

Main Results:

The therapy demonstrates excellent efficacy in treating recurrent pediatric acute lymphoblastic leukemia (ALL).
Achieves long-term remission, potentially leading to a cure for some patients.
High treatment cost is noted but considered consistent with the substantial clinical benefit.

Conclusions:

CAR-T therapy, despite its complexity and expense, is a highly effective treatment for specific pediatric cancers.
CAR-T therapies are expected to become increasingly important in the landscape of cancer treatment.